**Brainstorm Cell Therapeutics Inc. Reports Financial Results for Fiscal Year 2025**

Brainstorm Cell Therapeutics Inc., a biotechnology company focused on developing cell therapies for neurodegenerative diseases, reported a net loss of $10.31 million for the year ended December 31, 2025, compared to a net loss of $11.62 million for the previous fiscal year. The company did not generate any revenue from operations in either 2025 or 2024. Research and development expenses, net, totaled $4.18 million in 2025, a decrease from $4.65 million in 2024, primarily due to reduced costs related to clinical activities suppliers, materials, and clean room facilities, partially offset by increased stock-based compensation expenses. General and administrative expenses decreased to $5.78 million in 2025 from $7.04 million in 2024, mainly due to lower payroll, travel, and consultant costs, partially offset by increased stock-based compensation expenses.

The company's financial expenses increased to $533,000 in 2025 from $77,000 in 2024, driven by interest paid for loans and conversion exchange rates. Basic and diluted net loss per share was $1.11 for 2025, compared to $2.31 for 2024. The weighted average number of common shares outstanding used in computing basic and diluted net loss per share increased to 9,268,976 in 2025 from 5,021,798 in 2024, due to the issuance of shares to employees, directors, and through the Distribution Agreement and private placements. As of December 31, 2025, cash, cash equivalents, and restricted cash totaled $276,000.

Operationally, Brainstorm continued to focus on its NurOwn® technology, an autologous cellular therapy platform. A key development was the FDA's agreement, under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in ALS. The company also reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of the Phase 3b clinical trial. However, the company faced challenges, including a delisting notification from Nasdaq due to non-compliance with minimum shareholder equity requirements, leading to a transfer of trading to the OTCQB Venture Market. The company employed 20 full-time employees across its U.S. and Israeli locations.

Looking ahead, Brainstorm intends to pursue regulatory approval for NurOwn® in ALS, including the potential submission of a Biologics License Application (BLA) to the FDA following the successful completion of its Phase 3b clinical trial. The company is also strategically expanding its exosome-based platform technology to explore new therapeutic applications. The company acknowledges the need for substantial additional funding to pursue its business objectives and continue its operations, and is considering multiple financing alternatives.

About BRAINSTORM CELL THERAPEUTICS INC.

BrainStorm Cell Therapeutics Inc. is a biotechnology company specializing in autologous cellular therapies for neurodegenerative diseases such as ALS, progressive multiple sclerosis, and Alzheimer’s. Its proprietary NurOwn® platform uses patients’ own bone marrow-derived mesenchymal stem cells induced to secrete neurotrophic factors, aiming to modulate neuroinflammation, promote neuronal survival, and improve neurological function. The company focuses on clinical development, manufacturing, and commercialization of these cell therapies primarily in the U.S. and Europe.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.